A Phase 2 interventional study of HRS-2129 Tablet and HRS-2129 Tablet in Acute Gouty Arthritis, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Arthritis, Gouty with a site in China — 5 open to participants now, 6 under way, none of them phase 3. Arthritis, Gouty · China.
Among the 11 studies in Arthritis, Gouty with a site in China, this one is the 8th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 2, and was the 10th registered.
47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.
Browse Arthritis, Gouty studies →5 of the 11 studies in Arthritis, Gouty with a site in China are open now. Recruiting first, the newest first:
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–75
TJ Biopharma Co., Ltd. · Sites in China
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+ · Healthy volunteers
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18–45 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Arthritis, Gouty studies recruiting now, 8 (80%) set no upper age limit and 1 (10%) stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 90 is below the median of 140 across 35 interventional studies indexed under Arthritis, Gouty.
Median enrollment 134 across the 10 interventional studies, 500 across the 1 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 9 most frequent:
This study is registered under Shandong Suncadia Medicine Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 1 study filed under Arthritis, Gouty — fewer than ten, so there is no comparison to draw.
1 of the studies in Arthritis, Gouty with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07842497Innovent Biologics (Suzhou) Co. Ltd.A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis | 2027-05-11 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Arthritis, Gouty with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS-2129 Tablet
Drug: HRS-2129 Tablet
Drug: Placebo
HRS-2129 Tablet; high dose
HRS-2129 Tablet; low dose
HRS-2129 Tablet Placebo
Change from baseline inVisual Analogous Scale pain score at 24 hours post first dose
VAS,Visual Analogue Score is an often-used tool to measure subjective phenomena, which has shown good reliability and validity in terms of assessment of pain. In the clinical study of acute gout attack,it can be used as a tool to measure the degree of pain from 0 to 100 mm (with 0 being no pain and 100 being maximum pain)
Time frame: from ICF signing date to 24 hours after first dose
Change from baseline in VAS pain score at 1 hour, 2 hours, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours post first dose
Time frame: from ICF signing date to 1 hour, 2 hours, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours after first dose
Time until complete disappearance of pain in the target joint
Time frame: from ICF signing date to 15 days after first dose
Mean daily VAS pain score change from baseline (on-treatment)
Time frame: from ICF signing date to 15 days after first dose
Safety:Incidence and severity of AE/SAE
Time frame: from ICF signing date to day 14 after last dose(14 days)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-2129
Shandong Suncadia Medicine Co., Ltd. →